We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

83 hedge funds and large institutions have $206M invested in Applied Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,082% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $510K

700% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 4

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

93% more capital invested

Capital invested by funds: $107M → $206M (+$99M)

51% more funds holding

Funds holding: 5583 (+28)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

11.56% more ownership

Funds ownership: 68.08%79.64% (+12%)

Holders
83
Holders Change
+28
Holders Change %
+50.91%
% of All Funds
1.21%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
32
Increased
27
Reduced
11
Closed
4
Calls
$26.4M
Puts
$510K
Net Calls
+$25.9M
Net Calls Change
+$6.01M
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
51
Bank of America
North Carolina
$150K +$111K +44,403 +19,475%
WA
52
WealthTrust Axiom
Pennsylvania
$144K
RZH
53
Relyea Zuckerberg Hanson
Connecticut
$134K
Bank of New York Mellon
54
Bank of New York Mellon
New York
$90.3K +$67.1K +26,960 New
SPS
55
Susquehanna Portfolio Strategies
Pennsylvania
$84.1K +$62.5K +25,095 New
BFM
56
Boothbay Fund Management
New York
$83.6K +$62.1K +24,964 New
Charles Schwab
57
Charles Schwab
California
$82.1K
JF
58
Jump Financial
Illinois
$81K +$60.2K +24,171 New
TRCT
59
Tower Research Capital (TRC)
New York
$77.6K -$30.5K -12,268 -35%
TSS
60
Two Sigma Securities
New York
$62.6K +$46.5K +18,687 New
Belvedere Trading
61
Belvedere Trading
Illinois
$61.1K +$45.4K +18,236 New
US Bancorp
62
US Bancorp
Minnesota
$60.6K
Walleye Capital
63
Walleye Capital
New York
$57K -$305K -122,381 -88%
Goldman Sachs
64
Goldman Sachs
New York
$56.1K +$41.7K +16,752 New
Group One Trading
65
Group One Trading
Illinois
$55.1K +$40.9K +16,445 New
Squarepoint
66
Squarepoint
New York
$46.6K +$34.6K +13,915 New
Commonwealth Equity Services
67
Commonwealth Equity Services
Massachusetts
$45K
Acadian Asset Management
68
Acadian Asset Management
Massachusetts
$45K +$34.1K +13,689 New
OAC
69
OMERS Administration Corp
Ontario, Canada
$43.9K +$32.6K +13,100 New
PIA
70
Perennial Investment Advisors
California
$38.9K
YIH
71
Y-Intercept (HK)
Hong Kong
$37K +$27.5K +11,048 New
Balyasny Asset Management
72
Balyasny Asset Management
Illinois
$35.5K +$26.4K +10,605 New
Wolverine Trading
73
Wolverine Trading
Illinois
$33.9K +$25.1K +10,105 New
IF
74
Intrua Financial
Texas
$33.6K +$25K +10,040 New
EFS
75
Essex Financial Services
Connecticut
$33.5K

APLT Hedge Fund Activity: Q4 2023 in Review

83 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q4 2023, worth a combined $206M — up 93% from $107M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new APLT positions and 4 closed out — a net gain of 28 holders — while 27 added to existing stakes and 11 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $10.2M. The largest seller was Armistice Capital, exiting entirely with an estimated $8.47M sold.

  • 83 institutional investors held Applied Therapeutics (APLT) as of Q4 2023, up from 55 in Q3 2023.
  • Funds reported $206M of Applied Therapeutics stock for Q4 2023, up 93% quarter-over-quarter.
  • 32 funds opened new Applied Therapeutics positions in Q4 2023 and 4 closed out, a net change of +28 holders.
  • The largest Applied Therapeutics buyer in Q4 2023 was Perceptive Advisors, an estimated $10.2M added.
  • The largest Applied Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $8.47M sold.

Based on aggregated 13F filings for Q4 2023.